

EXHIBIT D1a

June 2024 EBD Commission Meeting

Drug Name	Date Drug Considered by EBD Commission	Use	Current Setup	EBD Recommendation (based on input from EBRx and Navitus)	Impacted Members	Cost Details	EBD Commission Decision	Board of Finance Decision
STRIVERDI RESPIMAT INHALER	June 2024	COPD	Tier 3, QL = 1 inhaler/30 days	Tier 2, QL = 1 inhaler/30 days	0	WAC: \$260 per inhaler	Approve Recommendation	Approve Recommendation
SEREVENT DISKUS INHALER	June 2024	Asthma/COPD	Tier 2	Not Covered	2	WAC: \$424 per inhaler	Approve Recommendation	Approve Recommendation
ORAVIG TAB	June 2024	Antifungal	Tier 3	Not Covered	0	WAC: \$1,200 per course	Approve Recommendation	Approve Recommendation
TOLMETIN TAB	June 2024	RA/OA	Tier 3	Not Covered	0	WAC: \$990-\$2,970 per month	Approve Recommendation	Approve Recommendation
TOLMETIN CAP	June 2024	RA/OA	Tier 3	Not Covered	0	WAC: \$990-\$2,970 per month	Approve Recommendation	Approve Recommendation
NEXLETOL TAB	June 2024	Cholesterol/CVD	Tier 2, PA, QL = 1 tab/day	Tier 2, ST (statin), QL = 1 tab/day	9	Avg: \$383 per month	Approve Recommendation	Approve Recommendation
NEXLIZET TAB	June 2024	Cholesterol/CVD	Tier 2, PA, QL = 1 tab/day	Tier 2, ST (statin), QL = 1 tab/day	0	Avg: \$409 per month	Approve Recommendation	Approve Recommendation
REPATHA INJ	June 2024	Cholesterol/CVD	Tier 2, PA, QL = 2 inj/28 days	Tier 2, ST (statin), QL = 2 inj/28 days	210	Avg: \$559 per month	Approve Recommendation	Approve Recommendation
REPATHA PUSHTRONEX INJ	June 2024	Cholesterol/CVD	Tier 2, PA, QL = 1 inj/28 days	Tier 2, ST (statin), QL = 1 inj/28 days	4	Avg: \$593 per month	Approve Recommendation	Approve Recommendation
ADALIMUMAB-AATY	June 2024	Various inflammatory diseases	Not Covered	Tier 4, PA, QL	295 on Humira	WAC: ~\$1,000 per month	Approve Recommendation	Approve Recommendation
SPIRIVA RESPIMAT 1.25 MCG/ACT	June 2024	Asthma	Tier 2, QL = 1 inhaler/30 days	Tier 2, QL = 1 inhaler/30 days, ST (ICS)	49	Avg: \$495 per month	Approve Recommendation	Approve Recommendation
PAXLOVID TAB (Emergency Use Authorization (EUA) version)	June 2024	COVID-19	\$0	Remove from formulary	Varies	Non-EUA product: \$1,390 per course	Approve Recommendation	Approve Recommendation
ZURZUVAE CAP	June 2024	Depression	Not Covered	Tier 4, PA, QL	0	Avg: \$14,500 per course	Approve Recommendation	Approve Recommendation
ENTYVIO INJ	June 2024	Ulcerative Colitis	Not Covered	Tier 4, PA, QL	1	Avg: \$5,478 per month	Approve Recommendation	Approve Recommendation
TRUQAP TAB	June 2024	Breast Cancer	Not Covered	Tier 4, PA, QL	0	Avg: \$22,990 per month	Approve Recommendation	Approve Recommendation
FRUZAQLA TAB	June 2024	Colorectal Cancer	Not Covered	Tier 4, PA, QL	1	Avg: \$25,200/month	Approve Recommendation	Approve Recommendation